These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 10526561)

  • 21. Zolmitriptan (Zomig, 311C90), a novel dual central and peripheral 5HT1B/1D agonist: an overview of efficacy.
    Schoenen J; Sawyer J
    Cephalalgia; 1997 Oct; 17 Suppl 18():28-40. PubMed ID: 9399015
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pre-clinical pharmacology of zolmitriptan (Zomig; formerly 311C90), a centrally and peripherally acting 5HT1B/1D agonist for migraine.
    Martin GR
    Cephalalgia; 1997 Oct; 17 Suppl 18():4-14. PubMed ID: 9399012
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Is a central action of acute antimigraine drugs essential?
    Goadsby PJ
    Cephalalgia; 1997 Jun; 17 Suppl 17():10-1. PubMed ID: 9218879
    [No Abstract]   [Full Text] [Related]  

  • 24. New "triptans" and other drugs for migraine.
    Med Lett Drugs Ther; 1998 Oct; 40(1037):97-100. PubMed ID: 9793036
    [No Abstract]   [Full Text] [Related]  

  • 25. Zolmitriptan provides consistent migraine relief when used in the long-term.
    Tuchman M; Edvinsson L; Geraud G; Korczyn A; Mauskop A; Pfaffenrath V
    Curr Med Res Opin; 1999; 15(4):272-81. PubMed ID: 10640259
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The clinical effectiveness of 311C90 in the acute treatment of migraine.
    Ferrari MD
    Eur Neurol; 1996; 36 Suppl 2():4-7. PubMed ID: 8791025
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 311C90: patient profiles and typical case histories of migraine management.
    Dowson AJ
    Neurology; 1997 Mar; 48(3 Suppl 3):S29-33. PubMed ID: 9071268
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Measuring central action of acute antimigraine drugs in humans.
    Schoenen J
    Cephalalgia; 1997 Jun; 17 Suppl 17():12-5; discussion 15-6. PubMed ID: 9218880
    [No Abstract]   [Full Text] [Related]  

  • 29. Profiles of 5-HT 1B/1D agonists in acute migraine with special reference to second generation agents.
    Deleu D; Hanssens Y
    Acta Neurol Belg; 1999 Jun; 99(2):85-95. PubMed ID: 10427351
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Zolmitriptan reverses blink reflex changes induced during the migraine attack in humans.
    de Tommaso M; Guido M; Libro G; Sciruicchio V; Puca F
    Neurosci Lett; 2000 Jul; 289(1):57-60. PubMed ID: 10899408
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 311C90: increasing the options for therapy with effective acute antimigraine 5HT1B/1D receptor agonists.
    Ferrari MD
    Neurology; 1997 Mar; 48(3 Suppl 3):S21-4. PubMed ID: 9071266
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Spinal cord infarction during use of zolmitriptan: a case report.
    Vijayan N; Peacock JH
    Headache; 2000 Jan; 40(1):57-60. PubMed ID: 10759907
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Mechanism of action of zolmitriptan].
    Pascual J
    Neurologia; 1998 Oct; 13 Suppl 2():9-15. PubMed ID: 9859690
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Clinical efficacy of zolmitriptan in migraine].
    Leira R; Noya M
    Neurologia; 1998 Oct; 13 Suppl 2():16-24. PubMed ID: 9859691
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Measuring event-related potentials.
    Dixon R
    Cephalalgia; 1999 Jul; 19 Suppl 24():29-30; discussion 30-1. PubMed ID: 10526680
    [No Abstract]   [Full Text] [Related]  

  • 36. The novel anti-migraine compound zolmitriptan (Zomig 311C90) has no clinically significant interactions with paracetamol or metoclopramide.
    Seaber EJ; Ridout G; Layton G; Posner J; Peck RW
    Eur J Clin Pharmacol; 1997; 53(3-4):229-34. PubMed ID: 9476036
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Zolmitriptan: new perspectives in migraine therapy. Satellite symposium of the 11th Migraine Trust International Symposium, London, 10 September 1996].
    Fortschr Neurol Psychiatr; 1997 Feb; 65(2 Suppl):1-4. PubMed ID: 9131063
    [No Abstract]   [Full Text] [Related]  

  • 38. The pharmacokinetics and effects on blood pressure of multiple doses of the novel anti-migraine drug zolmitriptan (311C90) in healthy volunteers.
    Dixon R; Gillotin C; Gibbens M; Posner J; Peck RW
    Br J Clin Pharmacol; 1997 Mar; 43(3):273-81. PubMed ID: 9088582
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness analysis of stratified versus stepped care strategies for acute treatment of migraine: The Disability in Strategies for Care (DISC) Study.
    Sculpher M; Millson D; Meddis D; Poole L
    Pharmacoeconomics; 2002; 20(2):91-100. PubMed ID: 11888361
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 311C90 (Zolmitriptan), a novel centrally and peripheral acting oral 5-hydroxytryptamine-1D agonist: a comparison of its absorption during a migraine attack and in a migraine-free period.
    Thomsen LL; Dixon R; Lassen LH; Gibbens M; Langemark M; Bendtsen L; Daugaard D; Olesen J
    Cephalalgia; 1996 Jun; 16(4):270-5. PubMed ID: 8792040
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.